InVivo Therapeutics to Present at 23rd Annual Piper Jaffray Health Care Conference
22 November 2011 - 12:00PM
Business Wire
InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a
developer of groundbreaking technologies for the treatment of
spinal cord injuries (SCI), today announced CEO Frank Reynolds will
present InVivo’s most recent breakthroughs and provide a business
update to potential investors during the 23rd Annual Piper Jaffray
Health Care Conference. The invitation-only event is set for Nov.
29-30 at the New York Palace in New York, NY.
Reynolds will present an overview and answer questions about
InVivo’s innovative biomaterial scaffold technology on Wednesday,
November 30 at 3:30 p.m. The company is currently awaiting FDA
approval to move forward with its first human clinical study for
acute SCI treatment using its proprietary scaffold to provide
structural support to a damaged spinal cord to help prevent
paralysis and improve recovery and prognosis for patients. The
10-patient pilot study is expected to begin in early 2012.
Audio from Reynolds’ presentation will be simultaneously webcast
live at
http://www.corporate-ir.net/ireye/conflobby.zhtml?ticker=NVIV.OB&item_id=4.
In addition, both Reynolds and InVivo’s Director of Finance, Sean
Moran, will be available throughout the event for one-on-one
meetings with investors by appointment only. To schedule a meeting,
contact Jillian Jackson at Jillian.E.Jackson@pjc.com or via
phone at 612-303-6262 or Sharon Novak at
Sharon.A.Novak@pjc.com or via phone at 612-303-6226.
The Piper Jaffray Health Care Conference has a long history as
one of the nation’s premiere investment research events for
emerging health care technologies. The annual conference brings
together more than 275 of the most influential public and private
companies to present their forecasts and recent successes in the
biotechnology, pharmaceuticals, drug discovery, medical technology,
health care services, and medical diagnostics and devices sectors
to nearly 1,500 of the top institutional investors, equity
portfolio managers and research analysts from around the world. For
more information or to register, visit www.piperjaffray.com.
About InVivo Therapeutics
InVivo Therapeutics Holdings Corp. is focused on utilizing
polymers as a platform technology to develop treatments to improve
function in individuals paralyzed as a result of traumatic spinal
cord injury. The company was founded in 2005 on the basis of
proprietary technology co-invented by Robert Langer, ScD. Professor
at Massachusetts Institute of Technology, and Joseph P. Vacanti,
M.D., who is affiliated with Massachusetts General Hospital. In
2011, the company earned the prestigious David S. Apple Award from
the American Spinal Injury Association for its outstanding
contribution to spinal cord injury medicine. The publicly traded
company is headquartered in Cambridge, Mass. For more details,
visit www.invivotherapeutics.com.
Safe Harbor Statement
Any statements contained in this press release that do not
describe historical facts may constitute forward-looking statements
within the meaning of the federal securities laws. Any
forward-looking statements contained herein are based on current
expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company’s
ability to sell additional shares of common stock and warrants to
purchase common stock at additional closings, the Company’s ability
to develop, market and sell products based on its technology; the
expected benefits and efficacy of the Company’s products and
technology in connection with spinal cord injuries; the
availability of substantial additional funding for the Company to
continue its operations and to conduct research and development,
clinical studies and future product commercialization; and, the
Company’s business, research, product development, regulatory
approval, marketing and distribution plans and strategies. These
and other factors are identified and described in more detail in
our filings with the SEC, including our Form 10-K and Form 10-Qs
and our current reports on Form 8-K. We do not undertake to update
these forward-looking statements made by us.